Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000728480 | SCV000856059 | uncertain significance | not provided | 2017-07-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001430966 | SCV001633716 | likely benign | Cholestanol storage disease | 2025-01-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002397502 | SCV002708748 | uncertain significance | Cardiovascular phenotype | 2024-12-03 | criteria provided, single submitter | clinical testing | The c.1564G>A (p.V522M) alteration is located in exon 9 (coding exon 9) of the CYP27A1 gene. This alteration results from a G to A substitution at nucleotide position 1564, causing the valine (V) at amino acid position 522 to be replaced by a methionine (M). The p.V522M alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV000728480 | SCV005409026 | uncertain significance | not provided | 2024-04-02 | criteria provided, single submitter | clinical testing | PM2_moderate |